Home/Pipeline/Eclira Genuair (Acidinium Bromide)

Eclira Genuair (Acidinium Bromide)

COPD

MarketedActive

Key Facts

Indication

COPD

Phase

Marketed

Status

Active

Company

KYORIN Pharmaceutical

About KYORIN Pharmaceutical

KYORIN Pharmaceutical is a publicly listed Japanese pharmaceutical leader with a mission to contribute to people's health by addressing unmet medical needs. Founded in 1923 and publicly listed in 1999, the company has achieved significant scale with a market valuation of ~$94.8B, built on a foundation of established products in respiratory and urology. Its current strategy, outlined in the 'Vision 110' long-term plan, focuses on transforming its business structure to become a core innovator in new pharmaceuticals while expanding its healthcare portfolio.

View full company profile

Therapeutic Areas

Respiratory Urology Otolaryngology Infectious Disease Pain

Other COPD Drugs

Drug	Company	Phase	Status
Yupelri® (revefenacin)	Cleo Life Sciences	Approved	Supported early development CMC
Spiro Neuromodulation System	Spiro Medical	Phase 2	Active
VL-PX10 & VL-P22	Vitti Labs	Phase 2	Active
Solrikitug	Uniquity Bio	Phase 2	Active
CAL-4	Calyxha Biotechnologies	Discovery	Active
OligoG (Inhaled)	Algipharma	Phase 2	Active
Tozorakimab	AstraZeneca	Phase III	Active
ANORO ELLIPTA	Innoviva	Commercial	Royalty Revenue Generating
GB-0895	Generate Biomedicines	Phase 1	Active